{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T04:18:00Z","timestamp":1680668280412},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00120-023-02046-z","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T17:18:16Z","timestamp":1677172696000},"page":"369-375","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neue Therapieans\u00e4tze und Studien\u00fcbersicht beim metastasierten hormonsensitiven Prostatakarzinom","New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer"],"prefix":"10.1007","volume":"62","author":[{"given":"A.","family":"Isgandarov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Darr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Posdzich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. A.","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"2046_CR1","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1442-2042.2012.02997.x","volume":"19","author":"H Van Poppel","year":"2012","unstructured":"Van Poppel\u00a0H, Klotz\u00a0L (2012) Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol 19:594\u2013601","journal-title":"Int J Urol"},{"key":"2046_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney\u00a0CJ, Chen\u00a0YH, Carducci\u00a0M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N\u00a0Engl J Med 373:737\u2013746","journal-title":"N Engl J Med"},{"key":"2046_CR3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos\u00a0CE, Chen\u00a0YH, Carducci\u00a0MA et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J\u00a0Clin Oncol 36:1080\u20131087","journal-title":"J Clin Oncol"},{"key":"2046_CR4","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","volume":"30","author":"NW Clarke","year":"2019","unstructured":"Clarke\u00a0NW, Ali\u00a0A, Ingleby\u00a0FC et al (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 30:1992\u20132003","journal-title":"Ann Oncol"},{"key":"2046_CR5","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi\u00a0K, Tran\u00a0N, Fein\u00a0L et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20:686\u2013700","journal-title":"Lancet Oncol"},{"key":"2046_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James\u00a0ND et\u00a0al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N\u00a0Engl J Med 377:338\u2013351","journal-title":"N Engl J Med"},{"key":"2046_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi\u00a0KN, Agarwal\u00a0N, Bjartell\u00a0A et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N\u00a0Engl J Med 381:13\u201324","journal-title":"N Engl J Med"},{"key":"2046_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis\u00a0ID, Martin\u00a0AJ, Stockler\u00a0MR et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N\u00a0Engl J Med 381:121\u2013131","journal-title":"N Engl J Med"},{"key":"2046_CR9","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong\u00a0AJ, Szmulewitz\u00a0RZ, Petrylak\u00a0DP et al (2019) ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J\u00a0Clin Oncol 37:2974\u20132986","journal-title":"J Clin Oncol"},{"key":"2046_CR10","first-page":"8","volume-title":"ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC)","author":"MR Smith","year":"2018","unstructured":"Smith\u00a0MR et al (2018) ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC). ASCO-GU. San Francisco, S 8\u201310"},{"issue":"10336","key":"2046_CR11","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi\u00a0K, Galceran\u00a0CJ, Foulon\u00a0S et al (2022) LBA5 A phase III trial with a\u00a02\u00a0\u00d7 2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone, PEACE\u20111. LANCET 399(10336):1695\u20131707","journal-title":"LANCET"},{"issue":"6","key":"2046_CR12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","volume":"82","author":"T Yanagisawa","year":"2022","unstructured":"Yanagisawa\u00a0T et al (2022) Androgen receptor signaling inhibitors in addition to Docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur Urol 82(6):584\u2013598","journal-title":"Eur Urol"},{"key":"2046_CR13","doi-asserted-by":"publisher","first-page":"102441","DOI":"10.1016\/j.ctrv.2022.102441","volume":"110","author":"G Fallara","year":"2022","unstructured":"Fallara\u00a0G et al (2022) Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a\u00a0systematic review and meta-analysis. Cancer Treat Rev 110:102441","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"2046_CR14","doi-asserted-by":"publisher","first-page":"P1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau\u00a0JP et al (2022) PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a\u00a0biomarker analysis from a\u00a0randomised, open-label, phase 2 trial. Lancet Oncol 23(11):P1389\u2013P1397","journal-title":"Lancet Oncol"},{"issue":"11","key":"2046_CR15","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","volume":"11","author":"S Carreira","year":"2021","unstructured":"Carreira\u00a0S et al (2021) Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP\u2011B trial. Cancer Discov 11(11):2812\u20132827","journal-title":"Cancer Discov"},{"key":"2046_CR16","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor\u00a0O, de Bono\u00a0J, Chi\u00a0KN et al (2021) Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N\u00a0Engl J Med 385:1091\u20131103","journal-title":"N Engl J Med"},{"issue":"9","key":"2046_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.2022.40.6_suppl.011","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke\u00a0NW et al (2022) Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). NEJM Evid 1(9):11. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.011","journal-title":"NEJM Evid"},{"issue":"6_suppl","key":"2046_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.2022.40.6_suppl.012","volume":"40","author":"CN Kim","year":"2022","unstructured":"Kim\u00a0CN et al (2022) Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. J\u00a0Clin Oncol 40(6_suppl):12\u201312","journal-title":"J Clin Oncol"},{"issue":"4","key":"2046_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2217\/fon-2021-0811","volume":"18","author":"N Agarwal","year":"2022","unstructured":"Agarwal\u00a0N et al (2022) Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO\u20112 phase III Study design. Future Oncol 18(4):425","journal-title":"Future Oncol"},{"key":"2046_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrurol.2018.9","volume":"15","author":"T Jamaspishvili","year":"2018","unstructured":"Jamaspishvili\u00a0T et\u00a0al (2018) Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol 15:222\u2013234","journal-title":"Nat Rev Urol"},{"key":"2046_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney\u00a0C et al (2021) Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): A multicentre, randomised, double-blind, phase 3 trial. Lancet 398:131\u2013142","journal-title":"Lancet"},{"key":"2046_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS178","author":"K Fizazi","year":"2021","unstructured":"Fizazi K et al (2021) A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281). Journal of Clinical Oncology 39(6_suppl). https:\/\/doi.org\/10.1200\/JCO.2021.39.6_suppl.TPS178","journal-title":"Journal of Clinical Oncology"},{"key":"2046_CR23","volume-title":"CYCLONE 3: a phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk mHSPC","author":"R Mckay","year":"2022","unstructured":"Mckay\u00a0R et al (2022) CYCLONE 3: a phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk mHSPC. ESMO 2022."}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-023-02046-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-023-02046-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-023-02046-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T12:22:25Z","timestamp":1680610945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-023-02046-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2046"],"URL":"https:\/\/doi.org\/10.1007\/s00120-023-02046-z","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"24 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Darr: Janssen-Cilag, IPSEN. K.\u00a0Hermann: Bayer, Sofie Biosciences, SIRTEX, Adacap, Curium, Endocyte, IPSEN, Siemens Healthineers, GE Healthcare, Amgen, Novartis, ymabs, Aktis Oncology, Theragnostics, Pharma15, Debiopharm, ABX, BTG, AstraZeneca, Janssen. B.A.\u00a0Hadaschik: ABX, AAA\/Novartis, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen R&D, Lightpoint Medical, Inc., Pfizer, German Research Foundation. V.\u00a0Gr\u00fcnwald: AstraZeneca, BMS, Novartis, Apogepha, Ipsen, EISAI, MSD, MerckSerono, Roche, EUSAPharm, Jannsen, Nanobiotix, ONO Pharmaceutical, Debiopharm und Pfizer. A.\u00a0Isgandarov und P.\u00a0Posdzich geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}